A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials
Open Access
- 9 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 8, 637378
- https://doi.org/10.3389/fmolb.2021.637378
Abstract
The COVID-19 is affecting thousands of peoples day by day and continues to spread across the world. The present review has focused on promising repurposing drugs, including remdesivir, lopinvar/retinovar, favipiravir, hydroxychloroquine, monoclonal antibodies and vaccines against the SARS-CoV-2 infection. Besides, our review has also focused on many organizations that are in the race to develop vaccines using various approaches including DNA, RNA, viral vectors and subunit proteins against this highly contagious respiratory disease. The spike protein is being studied by scientists all over the world to develop potential vaccines. The antiviral drugs, antibodies and vaccines developed by various researchers around the world have entered clinical trials in humans. The current clinical trials for antiviral agents and vaccines with promising outcomes are being discussed. So far, four vaccines developed by the Pfizer-BioNTech vaccine, the Johnson and Johnson vaccine and two AstraZeneca vaccines (produced by SKBio in the Republic of Korea and Serum Institute of India) are approved by the World Health Organization for public use.Keywords
This publication has 28 references indexed in Scilit:
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Tocilizumab treatment in COVID‐19: A single center experienceJournal of Medical Virology, 2020
- No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infectionMedecine Et Maladies Infectieuses, 2020
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control StudyEngineering, 2020
- COVID-19 infection: Emergence, transmission, and characteristics of human coronavirusesJournal of Advanced Research, 2020
- Discovering drugs to treat coronavirus disease 2019 (COVID-19)Drug Discoveries & Therapeutics, 2020
- Department of ErrorThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infectionsAntiviral Research, 2009